Theranos: How Did a $9 Billion Health Tech Startup End Up DOA?

by Ernesto Dal Bó and Guo Xu

Stanford University drop-out Elizabeth Holmes hoped to disrupt the traditional $75 billion blood-testing business with only one drop from a finger prick instead of several vials of blood. The revolutionary claim of Theranos’ founder was that her groundbreaking technology enabled a full range of laboratory tests from a tiny sample. The Silicon Valley company, founded in 2003, assembled a powerful board and high-profile investors, becoming a media darling valued at $9 billion. By 2018, federal prosecutors filed criminal charges alleging Holmes had defrauded investors and misled doctors and patients. The health technology company crashed from unicorn status leaving questions about what factors silenced doubters and enticed high-profile investors.


Pub Date: February 1, 2021

Discipline: Ethics

Subjects: Innovation, Health Care, Ethics, Technology

Product #: B5968-PDF-ENG

Industry: Technology, Health Care

Geography: Silicon Valley

Length: 6 page(s)

California Management Review

Berkeley-Haas's Premier Management Journal

Published at Berkeley Haas for more than sixty years, California Management Review seeks to share knowledge that challenges convention and shows a better way of doing business.

Learn more
Follow Us